/ Ensure your supplements are third-party tested for purity
According to the Ozempic Summary of Product Characteristics, approved injection sites include the abdomen, thigh, or upper arm
The 37.5 percent figure for class 3 obesity entrants who exited clinical obesity entirely is the more remarkable subset result, because those are the patients with the most metabolic burden and the most baseline weight to shed, and the historical pharmacological track record on that population has been close to nil.
Rajesh Malik Your Wegovy treatment plan is developed and personally monitored by Dr
Additionally, patients with type 2 diabetes often take other medications, such as diuretics or insulin, which can independently affect potassium levels
Current biosimilar development status (as of April 2026): At least 6 companies have filed Investigational New Drug (IND) applications for biosimilar semaglutide with the FDA Leading candidates: Sandoz (filed IND March 2024), Teva (filed IND August 2024), Biocon (filed IND November 2024) Earliest possible FDA approval: Q4 2027 for Sandoz if Phase 3 trials meet endpoints Manufacturing implications: Biosimilar manufacturers will need to build or contract fill-finish capacity (API production can use existing biologics facilities) Most biosimilar manufacturers are partnering with contract development and manufacturing organizations (CDMOs) rather than building dedicated facilities Expected biosimilar pricing: 30-50% below Wegovy list price based on insulin biosimilar precedent The patent thicket: Novo Nordisk holds 50+ patents covering semaglutide, including formulation patents, manufacturing process patents, and pen device patents Biosimilar manufacturers will need to design around device patents (likely using vial-and-syringe format initially) Patent litigation will likely delay first biosimilar launch by 12-24 months past initial FDA approval Prediction: The first biosimilar semaglutide will receive FDA approval in Q4 2027 but won't reach pharmacies until Q2 2028 due to patent litigation and manufacturing scale-up
